Back To News

OMEZA Hires Chief Commercial Officer with Decades of Experience in Advanced Woundcare

NEWS PROVIDED BY
OMEZA LLC
Aug 17, 2026, 07:58 ET

Transforming Wound Care Through Marine Science Omeza® Holdings, Inc. is a U.S.-based
ocean biotechnology company developing and commercializing marine-derived peptides and
lipid products, with an FDA-cleared product, OCM™, already on the market and ongoing
clinical programs to expand reimbursement and indications. Omeza products are formulated and
manufactured in the USA.

SARASOTA, Fla., Aug. 17, 2026 /PRNewswire-PRWeb/ — Justin Larrick brings more than 20
years of commercial leadership experience across biotechnology, regenerative medicine, medical
device, and healthcare technology. With a career rooted in wound care and regenerative
medicine, Justin brings proven capabilities including developing compliant commercial strategy,
market access, sales, marketing, and healthcare technology processes. His experience positions
him to help advance OMEZA’s commercial strategy and expand the reach and adoption of its
innovative solutions. Throughout his career, he has built and led high-performing commercial
organizations and developed strategies focused on accelerating revenue growth, expanding
market access, and scaling commercial infrastructure.

Prior to joining OMEZA, Justin served as Chief Commercial Officer of Innovative Wound
Consultants & MD DME, where he provided national leadership for advanced wound care,
surgical, and DME commercial strategy and growth. He played a key role in the development,
commercialization, and launch of HealCore AI and MD DME.

“Justin is a thoughtful and respected commercial leader in our industry. He
will ensure our company’s commercial success as we navigate the changing
landscape of advanced wound care. We are thrilled to be working with Justin
as a key leader here at OMEZA.” Cynthia Flowers, CEO

Previously, Justin spent more than 15 years at Organogenesis, where he held positions of
increasing responsibility, most recently serving as Vice President of Sales. He led national
commercial organizations across the advanced wound care and surgical markets and was
instrumental in expanding buy-and-bill market access, developing new channels of care,
launching multiple products, and building commercial capabilities to support sustained growth.
He also collaborated across finance, manufacturing, marketing, and medical functions to execute
growth strategies. From 2020 through 2023, as a senior leader at Organogenesis, he helped drive
$190 million in revenue growth, culminating in annual revenue of $450 million.